CN102643230B - 7-site substituted quinolone compound and application thereof in preparation of anti-tumor medicaments - Google Patents
7-site substituted quinolone compound and application thereof in preparation of anti-tumor medicaments Download PDFInfo
- Publication number
- CN102643230B CN102643230B CN201210093123.5A CN201210093123A CN102643230B CN 102643230 B CN102643230 B CN 102643230B CN 201210093123 A CN201210093123 A CN 201210093123A CN 102643230 B CN102643230 B CN 102643230B
- Authority
- CN
- China
- Prior art keywords
- warming
- cyclopropyl
- phenyl
- application
- substituted quinolone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 quinolone compound Chemical class 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title claims abstract description 10
- 230000000259 anti-tumor effect Effects 0.000 title description 6
- 238000002360 preparation method Methods 0.000 title description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 8
- 201000005202 lung cancer Diseases 0.000 claims abstract description 8
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 5
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 24
- 150000007660 quinolones Chemical class 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 230000000719 anti-leukaemic effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 208000032839 leukemia Diseases 0.000 abstract description 6
- 230000001472 cytotoxic effect Effects 0.000 abstract description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 56
- 238000010792 warming Methods 0.000 description 42
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 31
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 18
- 239000012065 filter cake Substances 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 238000001953 recrystallisation Methods 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 238000005406 washing Methods 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 14
- 239000013078 crystal Substances 0.000 description 14
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- JJWDELPVPRCLQN-UHFFFAOYSA-N 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;hydrochloride Chemical compound Cl.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 JJWDELPVPRCLQN-UHFFFAOYSA-N 0.000 description 8
- 229960003405 ciprofloxacin Drugs 0.000 description 8
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 8
- 239000000523 sample Substances 0.000 description 6
- LISFMEBWQUVKPJ-UHFFFAOYSA-N carbostyril Natural products C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 5
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical class ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 3
- 208000019065 cervical carcinoma Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- ZIZGWNOAHUCACM-UHFFFAOYSA-N 2-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=CC=C1S(Cl)(=O)=O ZIZGWNOAHUCACM-UHFFFAOYSA-N 0.000 description 2
- KMVZDSQHLDGKGV-UHFFFAOYSA-N 2-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=CC=C1S(Cl)(=O)=O KMVZDSQHLDGKGV-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- OINWZUJVEXUHCC-UHFFFAOYSA-N 3-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=CC(S(Cl)(=O)=O)=C1 OINWZUJVEXUHCC-UHFFFAOYSA-N 0.000 description 2
- OZDCZHDOIBUGAJ-UHFFFAOYSA-N 4-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=C(S(Cl)(=O)=O)C=C1 OZDCZHDOIBUGAJ-UHFFFAOYSA-N 0.000 description 2
- ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- HGDWHTASNMRJMP-UHFFFAOYSA-N [1-(hydroxyamino)-1-oxo-5-(3-phenoxyphenyl)pentan-2-yl]phosphonic acid Chemical compound ONC(=O)C(P(O)(O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 HGDWHTASNMRJMP-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 244000071493 Iris tectorum Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210093123.5A CN102643230B (en) | 2012-03-31 | 2012-03-31 | 7-site substituted quinolone compound and application thereof in preparation of anti-tumor medicaments |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210093123.5A CN102643230B (en) | 2012-03-31 | 2012-03-31 | 7-site substituted quinolone compound and application thereof in preparation of anti-tumor medicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102643230A CN102643230A (en) | 2012-08-22 |
CN102643230B true CN102643230B (en) | 2014-06-18 |
Family
ID=46656344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210093123.5A Expired - Fee Related CN102643230B (en) | 2012-03-31 | 2012-03-31 | 7-site substituted quinolone compound and application thereof in preparation of anti-tumor medicaments |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102643230B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110974968B (en) * | 2019-12-11 | 2021-03-26 | 中山万远新药研发有限公司 | Quinolone compound-containing composition and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW301607B (en) * | 1993-03-09 | 1997-04-01 | Takeda Pharm Industry Co Ltd | |
WO2011094260A2 (en) * | 2010-01-26 | 2011-08-04 | Stc. Unm | Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer |
-
2012
- 2012-03-31 CN CN201210093123.5A patent/CN102643230B/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102643230A (en) | 2012-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100832593B1 (en) | Quinazoline derivatives as an signal trnasduction inhibitor and method for the preparation thereof | |
CN102311434B (en) | Evodiamine compounds, preparation method thereof and application thereof | |
CN1807413B (en) | Carbazole sulfonamide derivative and its preparation method | |
CN103694238B (en) | NO donor type matrine derivative and preparation method and medical application thereof | |
CN107973791A (en) | Condensed ring or tricyclic Arylpyrimidines compound are used as kinase inhibitor | |
CA3032544A1 (en) | Ido1 inhibitor and preparation method and application thereof | |
CA2909310A1 (en) | Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways | |
CN106432190B (en) | The naphthalimide compound of one kind aminopyrimidine containing 2-, preparation method and application | |
WO2015151490A1 (en) | New tricyclic quinone derivative | |
CN111454252B (en) | Aromatic ring/aromatic heterocycle-triazole-methylene-TCP derivative and preparation method and application thereof | |
WO2015172196A1 (en) | Heterocyclic compounds and use of same | |
CN102070595A (en) | Substituted benzoxanthone type compound and application thereof | |
CN104072493B (en) | One class contains 2-mercaptobenzothiazole and the naphthalimide compound of triazole heterocycle, its preparation method and application thereof | |
CN105705493A (en) | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | |
TW580498B (en) | A novel amide compound and a pharmaceutical composition containing the same | |
CN103601670A (en) | Piplartine analogue, and preparation method and application thereof | |
TW202122372A (en) | 2-aminoquinazolinone derivative | |
CN110023288B (en) | Crystal form, salt form and preparation method of tyrosine kinase inhibitor | |
CN103450176A (en) | Naphthalimide compound containing 2-(4-aminophenyl) benzothiazole and application thereof | |
CN102643230B (en) | 7-site substituted quinolone compound and application thereof in preparation of anti-tumor medicaments | |
CN105130897B (en) | The naphthalimide compound of a kind of nitrogenous sulphur substituent group, preparation method and application | |
CN103524421A (en) | Novel naphthoyl urea derivate and medical application thereof | |
CN104496896B (en) | The preparation and application of the Sorafenib derivative of the urea structure containing sulphonyl | |
CN104059062A (en) | Benzothiazole and triazolediheterocycle-containing fused ring compound and application thereof | |
CN103864680A (en) | Chloroxoquinoline derivatives with anti-tumor activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210408 Address after: 226300 266 Century Avenue, Nantong hi tech Zone, Nantong, Jiangsu Patentee after: NANTONG WOTE OPTOELECTRONICS TECHNOLOGY Co.,Ltd. Address before: Quzhou University, No.78, jiuhuabei Avenue, Quzhou City, Zhejiang Province Patentee before: QUZHOU University |
|
TR01 | Transfer of patent right |
Effective date of registration: 20210414 Address after: 226600 Huji Industrial Park, Hai'an City, Nantong City, Jiangsu Province Patentee after: Hai'an Zhongli environmental protection materials Co.,Ltd. Address before: 226300 266 Century Avenue, Nantong hi tech Zone, Nantong, Jiangsu Patentee before: NANTONG WOTE OPTOELECTRONICS TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220323 Address after: 226600 no.428, Zhennan Road, Hai'an street, Hai'an City, Nantong City, Jiangsu Province Patentee after: Nantong haixingrui Biotechnology Co.,Ltd. Address before: 226600 Huji Industrial Park, Hai'an City, Nantong City, Jiangsu Province Patentee before: Hai'an Zhongli environmental protection materials Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140618 |
|
CF01 | Termination of patent right due to non-payment of annual fee |